Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: May 15, 2009
Last updated: April 23, 2011
Last verified: March 2011

RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.

PURPOSE: This randomized phase II trial is studying the side effects of palonosetron hydrochloride and to see how well it works in preventing nausea and vomiting caused by radiation therapy in patients with primary abdominal cancer.

Condition Intervention Phase
Anal Cancer
Carcinoma of the Appendix
Colorectal Cancer
Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Gastric Cancer
Gastrointestinal Carcinoid Tumor
Liver Cancer
Nausea and Vomiting
Pancreatic Cancer
Primary Peritoneal Cavity Cancer
Small Intestine Cancer
Drug: palonosetron hydrochloride
Other: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Supportive Care
Official Title: A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Complete response (no episodes of nausea or vomiting) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to treatment failure, defined as a single episode of vomiting, daily nausea score of moderate or greater, or taking ≥ 3 prochlorperazine or haloperidol tablets per day [ Designated as safety issue: No ]
  • Proportion of patients reporting treatment failure [ Designated as safety issue: No ]
  • Tolerability and adverse events as assessed by NCI CTC v 3.0 [ Designated as safety issue: Yes ]
  • Average level of nausea reported and the proportion of patients experiencing a complete response independent of treatment arm [ Designated as safety issue: No ]

Estimated Enrollment: 75
Study Start Date: September 2009
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive palonosetron hydrochloride IV on day 1.
Drug: palonosetron hydrochloride
Given IV
Experimental: Arm II
Patients receive palonosetron hydrochloride IV on days 1 and 4.
Drug: palonosetron hydrochloride
Given IV
Placebo Comparator: Arm III
Patients receive placebo IV on day 1.
Other: placebo
Given IV
Placebo Comparator: Arm IV
Patients receive placebo IV on days 1 and 4.
Other: placebo
Given IV

Detailed Description:


  • Evaluate the rate of complete responses, defined as no vomiting and no nausea, in patients with primary gastrointestinal and/or retroperitoneal sarcomas treated with two different dosing schedules of palonosetron hydrochloride during abdominal radiotherapy as part of their cancer treatment.
  • Determine the tolerability of palonosetron hydrochloride vs placebo in these patients.
  • Validate patient diaries for assessing nausea and vomiting by comparing with alternative methods for measuring nausea and vomiting in order to determine the optimal approach for future studies.

OUTLINE: Patients are stratified according to planned radiotherapy duration (< 5 weeks vs ≥ 5 weeks), planned concurrent fluorouracil ( yes vs no), and gender. Patients are randomized to 1 of 4 treatment arms.

  • Arm I: Patients receive palonosetron hydrochloride IV on day 1.
  • Arm II: Patients receive palonosetron hydrochloride IV on days 1 and 4.
  • Arm III: Patients receive placebo IV on day 1.
  • Arm IV: Patients receive placebo IV on days 1 and 4. In all arms, courses repeat weekly during radiotherapy in the absence of disease progression or unacceptable toxicity.

Patients complete nausea and vomiting questionnaires and diaries at baseline and daily during radiotherapy. Patients also complete symptom experience diaries weekly during radiotherapy.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of primary gastrointestinal and/or retroperitoneal sarcoma
  • Scheduled to undergo ≥ 3000 cGy or ≥ 3 weeks of external beam radiation to the abdomen

    • Radiotherapy fields to extend between T11 and L3, and of a size ≥ 100 cm^2
  • No brain metastases


  • ECOG performance status 0-2
  • Negative pregnancy test
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • Able to complete questionnaire(s) alone or with assistance
  • Willing to return to NCCTG enrolling institution for follow-up
  • Able to reliably take oral medication (for purposes of rescue medication)
  • No hypersensitivity to palonosetron hydrochloride or other selective 5-HT3 receptor antagonists
  • No comorbid systemic illness or other severe concurrent disease that, in the judgment of the investigator, would make the patient inappropriate for study entry or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • No nausea ≤ 48 hours prior to study enrollment
  • No history of dystonic reactions to prochlorperazine or haloperidol or related agents


  • See Disease Characteristics
  • More than 7 days since prior agents known to have significant effects on emesis, including the following:

    • Ondansetron
    • Sedating antihistamines
    • Antipsychotics
    • Cannabinoids
    • Corticosteroids
    • Metoclopramide
    • Narcotic analgesics
    • Benzodiazepines
  • More than 7 days since prior chemotherapy other than fluorouracil or capecitabine used as a radiosensitizer
  • More than 7 days since of prior cetuximab
  • More than 7 days since prior and no concurrent oral steroids
  • No prior palonosetron hydrochloride
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00903396

  Show 69 Study Locations
Sponsors and Collaborators
North Central Cancer Treatment Group
Study Chair: Michele Yvette Halyard, MD Mayo Clinic
  More Information

Additional Information:
No publications provided Identifier: NCT00903396     History of Changes
Other Study ID Numbers: CDR0000642449, NCCTG-N08C2
Study First Received: May 15, 2009
Last Updated: April 23, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
nausea and vomiting
gastrointestinal carcinoid tumor
anal cancer
carcinoma of the appendix
colon cancer
rectal cancer
extrahepatic bile duct cancer
gallbladder cancer
gastric cancer
liver and intrahepatic biliary tract cancer
pancreatic cancer
small intestine cancer
primary peritoneal cavity cancer

Additional relevant MeSH terms:
Appendiceal Neoplasms
Bile Duct Neoplasms
Carcinoid Tumor
Gastrointestinal Neoplasms
Malignant Carcinoid Syndrome
Bile Duct Diseases
Biliary Tract Diseases
Biliary Tract Neoplasms
Cecal Diseases
Cecal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Signs and Symptoms
Signs and Symptoms, Digestive processed this record on March 26, 2015